[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurogenic-bladder-nb\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurogenic-bladder-nb":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100643017","early-phase-1-coupled-gentamicin-lactobacillus-rhamnosus-in-nlutd-100643017",false,"NCT07643974","Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD","Effect of Dose Timing of Coupled Intravesical Gentamicin and Lactobacillus Rhamnosus LGG on Success and Length of Colonization in Men and Women With SCI\u002FD and NLUTD","Inclusion Criteria:\n\n* Neurologic diagnosis\n* ≥18 years old\n* Neurogenic bladder for at least 6 months\n* No USQNB-IC A, B1, or B2 symptoms\n* No currently diagnosed UTI (within 24 hours of initiating instillations)\n* Community dwelling (not in acute hospital setting)\n\nExclusion Criteria:\n\n* Known genitourinary pathology beyond NLUTD (i.e. kidney stones, bladder stones, vesicoureteral reflux, etc.)\n* Use of prophylactic antibiotics or any antibiotics within 2 weeks of beginning instillations\n* Instillation of intravesical agents other than saline bladder wash\n* Immunodeficiency\n* Psychologic or psychiatric conditions influencing the ability to follow instructions\n* Allergy to ampicillin, daptomycin, gentamicin\u002Fgentamycin, or probiotics\n* Participation in another study which could confound results","ALL","18 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The main objective of the proposed research study is to determine in men and women with spinal cord injury\u002Fdisease and neurogenic bladder whether the dose of coupled gentamicin \\& Lactobacillus rhamnosus GG affects the recolonization of the bladder, and whether the rate of success differs by sex. Secondary objectives include determining whether that recolonization lasts 7, 14, or 28 days; and safety of the coupled gentamicin \\& Lactobacillus instillations.",[26,27,28,29,30,31],"Spinal Cord Injury","Neurogenic Bladder (NB)","Neurogenic Lower Urinary Tract Dysfunction","Multiple Sclerosis","Spina Bifida","Urinary Tract Infection(UTI)",[33,34,35,36,37,38,39],"gentamicin","gentamycin","lactobacillus","spinal cord injury","spinal cord disease","urinary tract infection","neurogenic bladder","NOT_YET_RECRUITING","2026-06-08",{"date":43,"type":44},"2026-06-12","ACTUAL",{"date":46,"type":20},"2026-06",{"date":48,"type":20},"2027-09",{"name":50,"class":51},"Medstar Health Research Institute","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100642982","radio-frequency-rf-bladder-monitor-100642982","NCT07639541","Radio-frequency (RF) Bladder Monitor","Inclusion Criteria:\n\n* Age \\> 18\n* Able\u002Fwilling to sit (or stand) in place for the time it takes for bladder to fill once.\n* No implanted devices\n* Able to toilet\u002Fvoid independently\n* No pregnancy\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Implanted devices (e.g., pacemakers)\n* Unable to toilet without assistance\n* Unable to stay relatively still for the time it takes bladder to fill once\n* Pregnancy",true,{"count":61,"type":20},40,[63],"NA","The goal of this pilot feasibility study is to evaluate a wearable microwave (MW)-based bladder monitoring system in adult volunteers and those with spinal cord injury (SCI) who use self-catheterization for bladder management. The study aims to learn whether the device can monitor bladder filling and estimate bladder volume non-invasively.\n\nThe main questions the study aims to answer are:\n\n1. Can the MW-based monitoring system distinguish between non-full and full bladder states?\n2. How accurately do MW-based bladder volume estimates agree with ultrasound bladder scans and voided urine volumes?\n3. Is the wearable monitoring system feasible, comfortable, and usable for individuals with SCI?\n\nParticipants will:\n\n1. Complete questionnaires about bladder symptoms and quality of life\n2. Wear up to six non-invasive MW sensors on the lower pelvic region\n3. Undergo two bladder filling and voiding cycles during the study visit\n4. Have MW measurements collected approximately every five minutes during bladder filling\n5. Undergo ultrasound bladder scans and bladder volume measurements for comparison\n6. Complete a post-study usability and comfort survey",[66,28,27],"Spinal Cord Injuries (SCI)",[26,68,28,69,70,71,72,73,74,75,76,77,78,79],"Neurogenic Bladder","Bladder Monitoring","Bladder Management","Microwave Sensing","Radio-Frequency Sensing","Wearable Medical Device","Bladder Fullness Detection","Bladder Volume Estimation","Non-Invasive Monitoring","Assistive Technology","Pilot Feasibility Study","Urology","2026-06-05",{"date":82,"type":44},"2026-06-10",{"date":84,"type":20},"2026-07-01",{"date":86,"type":20},"2027-03-31",{"name":88,"class":51},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":89},"100613306","home-neuromodulation-for-neurogenic-bladder-management-in-spinal-cord-injury-100613306","NCT07264868","Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury","Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury: A Hybrid Implementation-Efficacy Trial","Inclusion Criteria:\n\n* Non-progressive chronic (\\>1 year) SCI\n* Neurologic level of injury T9 and above\n* Stable over active bladder (OAB) medications (≥3 months)\n* No contraindication to MRI (per MRI Safety Questionnaire)\n* English or Spanish speaking\n* Tolerate and be able to evoke toe flexion bilaterally with transcutaneous tibial nerve stimulation (tTNS) (self or assisted)\n* Pass the tTNS competency checklist to perform or direct performance of tTNS.\n\nExclusion Criteria:\n\n* Ongoing\u002Factive genitourinary oncologic diagnoses\n* History of other central nervous system disorder (CNS) disorders and\u002For peripheral neuropathy\n* Pregnancy or planning to become pregnant.\n* Lower Motor Neuron bladder\n* Restorative bladder surgery such as augmentation cystoplasty\n* Botulinum toxin-A injections in the bladder within 6 months of trial enrolment (injection in other sites is allowed)\n* Anticoagulation treatment or prophylaxis\n* Advanced peripheral vascular disease (gangrene, amputation, etc.)\n* History of intolerance to electrical stimulation, particularly of the leg","75 Years",{"count":99,"type":20},21,[63],"The purpose of this study is to determine the safety and efficacy of Injectrode Tibial Nerve Stimulation for bladder function in people with spinal cord injury.",[103,27],"Spinal Cord Injury (SCI)","RECRUITING","2026-05-07",{"date":107,"type":44},"2026-05-11",{"date":105,"type":44},{"date":110,"type":20},"2028-09-01",{"name":112,"class":51},"The University of Texas Health Science Center, Houston"]